
A plague mysteriously spread from Europe into Asia 4,000 years ago. Scientists now think they may know how
For thousands of years, a disease repeatedly struck ancient Eurasia, quickly spreading far and wide. The bite of infected fleas that lived on rats passed on the plague in its most infamous form — the Black Death of the 14th century — to humans, and remains its most common form of transmission today.
During the Bronze Age, however, the plague bacterium, Yersinia pestis, had not yet developed the genetic tool kit that would allow later strains to be spread by fleas. Scientists have been baffled as to how the illness could have persisted at that time.
Now, an international team of researchers has recovered the first ancient Yersinia pestis genome from a nonhuman host — a Bronze Age domesticated sheep that lived around 4,000 years ago in what is now modern-day Russia. The discovery has allowed the scientists to better understand the transmission and ecology of the disease in the ancient past, leading them to believe that livestock played a role in its spread throughout Eurasia. The findings were published Monday in the journal Cell.
'Yersinia pestis is a zoonotic disease (transmitted between humans and animals) that emerged during prehistory, but so far the way that we have studied it using ancient DNA has been completely from human remains, which left us with a lot of questions and few answers about how humans were getting infected,' said lead author Ian Light-Maka, a doctoral researcher at the Max Planck Institute for Infection Biology in Berlin. There have been nearly 200 Y. pestis genomes recovered from ancient humans, the researchers wrote.
Finding the ancient bacterium in an animal not only helps researchers understand how the bacterial lineage evolved, but it could also have implications for understanding modern diseases, Light-Maka added via email. 'Evolution can sometimes be 'lazy,' finding the same type of solution independently for a similar problem — the genetic tools that worked for pestis to thrive for over 2000 years across over Eurasia might be reused again.'
Unraveling the mystery of a Bronze Age plague
plague
Excavations on the Eurasian Steppe have yielded thousands of animal bones from Bronze Age livestock. Courtesy Taylor Hermes via CNN Newsource
The ancient bacterium that caused the Eurasia plague, known today as the Late Neolithic Bronze Age lineage, spread from Europe all the way to Mongolia, with evidence of the disease found across 6,000 kilometres (3,700 miles).
Recent evidence suggests that the majority of modern human diseases emerged within the last 10,000 years and coincided with the domestication of animals such as livestock and pets, according to a release from the German research institute. Scientists suspected that animals other than rodents were a part of the enormous puzzle of the Bronze Age plague transmission, but without any bacterial genomes recovered from animal hosts, it was not clear which ones.
To find the ancient plague genome, the study authors investigated Bronze Age animal remains from an archaeological site in Russia known as Arkaim. The settlement was once associated with a culture called Sintashta-Petrovka, known for its innovations in livestock. There, the researchers discovered the missing connection — the tooth of a 4,000-year-old sheep that was infected with the same plague bacteria found in humans from that area.
Finding infected livestock suggests that the domesticated sheep served as a bridge between the humans and infected wild animals, said Dr. Taylor Hermes, a study coauthor and an assistant professor of anthropology at the University of Arkansas.
'We're sort of unveiling this in real time and trying to get a sense for how Bronze Age nomadic herders out in the Eurasian Steppe were setting the stage for disease transmission that potentially led to impacts elsewhere,' Hermes said, 'not only in later in time, but also in a much more distant, distant landscape.'
During this time within the Eurasian Steppe, as many as 20% of the bodies in some cemeteries are those of people who were infected with, and most likely died from, the plague, making it an extremely pervasive disease, Hermes said. While livestock are seemingly a part of what made the disease so widespread, they are only one piece of the puzzle. The identification of the bacterial lineage in an animal opens new avenues for researching this disease's evolution as well as the later lineage that caused the Black Death in Europe and the plague that's still around today, he added.
plague
The Y. pestis genome was recovered from this 4,000 year old sheep tooth. Courtesy Taylor Hermes via CNN Newsource
'It's not surprising, but it is VERY cool to see (the DNA) isolated from an ancient animal. It's extremely difficult to find it in humans and even more so in animal remains, so this is really interesting and significant,' Hendrik Poinar, evolutionary geneticist and director of the Ancient DNA Centre at McMaster University in Hamilton, Ontario, wrote in an email. Poinar was not involved with the study.
It is likely that humans and animals were passing the strains back and forth, but it isn't clear how they did so — or how sheep were infected in the first place. It is possible sheep picked up the bacteria through a food or water source and then transmitted the disease to humans via the animal's contaminated meat, he added.
'I think it shows how extremely successful (if you want to label it that way) this particular pathogen has been,' Poinar added. He, as well as the study's authors, said they hope that further research uncovers other animals infected with the ancient strain to further the understanding of the disease's spread and evolution.
Ancient plague to modern plague
While the plague lineage that persisted during the Bronze Age is extinct, Yersinia pestis is still around in parts of Africa and Asia as well as the western United States, Brazil and Peru. But it's rare to encounter the bacteria, with only 1,000 to 2,000 cases of plague annually worldwide.
There is no need for alarm when it comes to dealing with livestock and pets, Hermes said. The findings are a reminder that animals carry diseases that are transmittable to humans. Be cautious when cooking meat, or to take care when bitten by an animal, he added.
'The takeaway is that humans aren't alone in disease, and this has been true for thousands of years. The ways we are drastically changing our environment and how wild and domesticated animals are connected to us have the potential to change how disease can come into our communities,' Light-Maka said. 'And if you see a dead prairie dog, maybe don't go and touch it.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
2 hours ago
- CTV News
Lawson's vice president of research no longer with organization, dogs remain under care of Lawson Research Institute
An internal email obtained by CTV News outlined that Lawson's vice president of research and scientific director, Lisa Porter, is no longer with the organization. Lawson also released a news release, outlining that dogs remain under the care of St. Joseph's Health Care's Lawson Research Institute, despite animal testing no longer taking place. Roy Butler, president and CEO of St. Joseph's Health Care, said in the email that Andrey Andreits, the interim director of research operations, will take on the responsibility of day-to-day operations. In regards to the dogs in the organization's care, Lawson said the Canadian Council on Animal Care and the Western Animal Care Committee are offering their oversight to ensure ethical research. 'As part of the studies, dogs were included in an enrichment program created by registered veterinary technologists to ensure they were socialized with each other and humans daily,' a news release read. 'They also had access to outdoor spaces and nutritious food. Although the research studies involving dogs have stopped, the care continues to be delivered for the dogs currently in our care.' Officials said research officials were overseen and 'careful management of pain was a top priority.' Lawson ensures all procedures were done under anaesthetic. More to come.


Globe and Mail
3 hours ago
- Globe and Mail
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca's total revenues) rose 18% in the second quarter of 2025, generating $6.3 billion in sales. In the first half of 2025, the Oncology segment generated almost $12 billion in revenues, which rose 16% year over year. The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with Merck MRK for Lynparza. AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $302 million in the first half of 2025, driven by demand growth in the second-line biomarker-altered population. AstraZeneca expects further growth for Truqap to be driven by increased uptake within the PIK3CA population and additional global launches. AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway witnessed encouraging early launch signals in the United States for the breast cancer indication in the first half, recording sales of $14 million. Important late-stage oncology candidates in AstraZeneca's pipeline are camizestrant (HR+ HER2- metastatic breast cancer), volrustomig (several types of cancers), sonesitatug vedotin (advanced or metastatic gastric or GEJ adenocarcinoma) and surovatamig (previously untreated follicular lymphoma). Regulatory applications seeking approval of Imfinzi for early-stage gastric and gastroesophageal junction cancers are under regulatory review. AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign. Our estimates for AstraZeneca's total oncology portfolio suggest a CAGR of around 11.1% over the next three years. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, Merck and Bristol-Myers BMY. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena, and the Braftovi-Mektovi combination. Pfizer's oncology revenues grew 9% in the first half of 2025. The addition of Seagen in 2023 also strengthened its position in oncology by adding four antibody-drug conjugates (ADCs) — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, ADCs and immuno-oncology biologics. Merck's key oncology medicines are PD-L1inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report


CTV News
5 hours ago
- CTV News
In Your Community: Miracle Treat Day
London Watch CTV London's Julie Atchison was joined by Milanah, a patient ambassador, at Dairy Queen for Miracle Treat Day.